Discover 1,972 paid clinical trials in Miramar, Florida. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,972
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
for
Ovarian Cancer
Location: West Palm Beach FL, Orlando FL, St. Petersburg FL,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT07059845
Phase 2, Recruiting
Active & Responsive
A Trial to Assess TEV-56286 at Different Doses in Healthy Participants
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
for
Rheumatoid Arthritis (RA)
Location: Cooper City FL, Miami Lakes FL, Hialeah FL, Miami FL,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18 - 70+
Code: NCT07258849
Phase 1, Recruiting
Active & Responsive
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
for
Primary Sjogren's Disease
Location: Cooper City FL, Miami FL, South Miami FL,
Sponsor: Vor Biopharma
Sex: All
Age: 18 - 70+
Code: NCT07404865
Phase 3, Recruiting
Active & Responsive
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
for
Lupus Nephritis, Systemic Lupus Erythematosus,
Location: Cooper City FL, Miami FL, Gainesville FL,
Sponsor: Fate Therapeutics
Sex: All
Age: 12 - 70
Code: NCT07570862
Phase 2, Recruiting
Active & Responsive
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
for
Heart Failure With Preserved Ejection Fraction,
Location: Pembroke Pines FL, Hollywood FL, Hialeah FL,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07037459
Phase 3, Recruiting
Active & Responsive
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity